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Pharmaceutics
liver diseases. It is also reported to be effective in certain 
cancers.[1-5] The poor aqueous solubility of the drug may 
lead to dissolution-related bioavailability problems. Many 
approaches such as solubilization with surfactant systems, 
formation of water soluble complexes, and use of pro-drugs 
and soluble salt formation have been reported for improving 
the solubility and dissolution, and in turn the bioavailability 
of the drug.[6-8] Cyclodextrin and its derivatives play an 
important role in the formulation development due to their 
effect on solubility, dissolution rate, chemical stability, and 
absorption of a drug.[9] Nagarsenkar et al. reported faster 
dissolution and better bioavailability of ketorolac solid 
dispersion with HP-b-CD.  [10] Reddy et al. reported enhanced 
solubility and dissolution rate of Celecoxib by complexation 
with b-Cyclodextrin.[11] The objective of the present 
study is to investigate the possibility of improving the 
solubility and dissolution rate of silymarin by complexation 
with b-cyclodextrin and also to compare the different 
complexation methods with respect to their dissolution 
INTRODUCTION
Silymarin (482.43) is not a good water soluble hepatoprotective 
agent. The oral absorption of silymarin is only about 23 – 
47%, leading to low bioavailability of the drug, which 
limits its use. It is a mixture of mainly three flavanolignans, 
namely, silybin, silydianin, and silicristine, with silybin being 
most active. silymarin has been used medicinally to treat 
liver disorders, including acute and chronic liver hepatitis, 
toxin –/drug-induced hepatitis and cirrhosis, and alcoholic 
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ABSTRACT
Silymarin is a hepatoprotective agent, having poor water solubility and oral absorption of about 23 – 47%, leading 
to low bioavailability of the drug. The aim of the present study is to improve the solubility and dissolution rate and in 
turn the hepatoprotective activity of the drug, by formulating its inclusion complex with beta (b)-cyclodextrin, using 
different methods. The phase solubility analysis indicates the formation of 1:1 molar inclusion complex of the drug 
with beta cyclodextrin. Apparent stability constant for Silymarin (Kc) was 722 K−1 with b-cyclodextrin complex. The 
inclusion complexes were prepared by four different methods, namely, physical mixing, kneading, co-precipitation, 
and solvent evaporation. The prepared complexes were characterized using differential scanning colorimetry, 
scanning electron microscopy, and x-ray diffractometry. The inclusion complex prepared by the co-precipitation 
methods exhibits an overall best result, with respect to the formulation of sustained release formulations.
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study. In addition, the physiochemical characteristics of 
solid inclusion complexes were also investigated.
MATERIALS AND METHODS
A gift sample of silymarin was obtained from AGAPE 
pharmaceuticals, Majhitar, East Sikkim; b-cyclodextrin 
was obtained from Zim Laboratories Ltd., Nagpur. HCl, 
methanol potassium dihydrogen phosphate, and sodium 
hydroxide were of analytical grade (Merck, Mumbai). All 
other chemicals and reagents used were of analytical grade.
Phase solubility analysis for silymarin
Phase solubility studies were performed to determine 
the stoichiometric proportions of silymarin with 
b-cyclodextrin.  [12,13] The data was used to determined the 
stability constant of the complexes. For this, the stock 
solution of 0.01 M b-cyclodextrin was prepared using 
distilled water. These stock solutions were diluted with 
distilled water to give molar solutions in the range of 0.002 
to 0.01 M b-cyclodextrin. Five ml of each molar solution 
was filled in screw capped vials and the excess quantity of 
the drug was added to each vial separately.[7,14] The vials 
were shaken at an ambient temperature, for 48 hours, using 
a laboratory shaker (Remi). The supernatant solutions were 
collected carefully and filtered using Whatman filter paper 
(No. 41). The concentration of the drug in filtered solutions 
was determined using a UV visible spectrophotometer. 
No changes in λ max of the drug were found after 
complexation with cyclodextrin, hence absorbance of the 
resultant solutions were recorded at 286 nm, which was λ 
max of the drug. From the slope and intercept value (S0) 
of the phase solubility curve, a stability constant (Kc) was 
determined.
KC = Slope/[S0 (1 − Slope)]
Preparation of physical mixture and inclusion 
complexes
Physical mixture method
The required molar (1 : 1) quantities of the drug and 
cyclodextrin were weighted accurately and mixed together 
thoroughly in a mortar, with vigorous trituration, for about 
three hours. These mixtures were then passed through 
sieve No. 44, and finally stored in airtight containers till 
further use.[7,15,16]
Kneading method
The required quantities of the drug (Silymarin) and 
b-cyclodextrin were weighed accurately in a ratio of 1:1. 
A homogenous paste of cyclodextrin was prepared in a 
mortar by adding water : Methanol mixture (1 : 1) in small 
quantities. Silymarin powder was then added to this paste 
in portions, with continuous kneading, for three hours. 
An appropriate quantity of water : Methanol mixture (1:1) 
was added further to maintain suitable consistency of the 
paste. This paste was dried in a hot air oven at 45∞–50∞ 
for 24 hours. The dried complexes were then powdered 
and passed through sieve No. 44 and stored in airtight 
containers till further use.[15]
Co-precipitation method
Quantities of drug and cyclodextrin, in the required 
molar ratio (1 : 1), were dissolved in methanol : Water, 
respectively. The solution of the drug was added dropwise 
into cyclodextrin solution. The contents were continuously 
stirred for 6 hours and finally were dried at 45∞– 50∞ for 
48 hours, collected, and stored in airtight containers till 
further use.[16]
Solvent evaporation method
In this technique, silymarin along with solubilizsing additives 
such as acetone were dissolved at 25∞C temperature. Next, 
the required moles of b-cyclodextrin in hot distilled water 
were added dropwise into this solution, with continuous 
stirring, for one hour. The complexes formed were filtered 
and dried under a vacuum. Then the prepared solid mass 
was stored in a desiccator under vacuum to a constant 
weight. The dried products were removed, pulverized, and 
passed through sieve No. 100 and finally stored in a closed 
airtight container.
Characterization of silymarin inclusion complexes
Drug content estimation
The quantities of inclusion complex equivalent to 70 mg of 
silymarin were dissolved in water: Methanol mixture (1:1). 
Appropriate dilutions were made and the drug content of 
each complex was calculated from UV absorbance recorded 
at λ max 286 nm.
Scanning electron microscopy
The morphology of the inclusion complexes by physical 
mixture, kneading method, and co-precipitation method 
was studied using a scanning electron microscope (JSM-
5610 LV Jeol, Japan). The samples were coated with 
platinum to provide a conductive layer for observing 
images at 15 kV.
IR spectrum analysis
Infra red (IR) spectra of the drug and inclusion complexes 
were recorded using the KBr method using Fourier Transform 
Infrared Spectrophotometer (FT IR-8400 S). A baseline Journal of Young Pharmacists Vol 3 / No 3  207
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correction was made using dried potassium bromide, and 
then the spectra of the dried mixtures of drug and inclusion 
complexes with potassium bromide were recorded.
Differential scanning calorimetric analysis
This scanning was performed using DSC model (Perkin 
Elmer). The samples were placed in a closed platinum 
crucible and DSC thermograms were recorded at a heating 
rate of 10o/minute in the range of 20o to 310oC.[16]
X-ray diffraction study
The X-ray diffraction pattern of the selected inclusion 
complex was compared with that of pure silymarin. 
This was performed by measuring 2θ in the range of 
4∞ to 50∞ with reproducibility of ±0∞–001∞ on an X-ray 
diffractometer (Phillips).
Dissolution study of silymarin and its inclusion complexes
Dissolution of inclusion complexes (equivalent to 70 mg 
of silymarin) was studied using the USP XXII eight 
station dissolution apparatus (Electrolab TDT-08L). 
The dissolution was carried out in 900 ml of Phosphate 
buffer, pH 6.8, at a speed of 75 rpm. Aliquots of 10 mL 
were withdrawn periodically and replaced with 10 mL 
of fresh dissolution medium. The concentrations of the 
drug in the samples were determined by measuring their 
absorbance at 286 nm, using Shimadzu 1700 UV-visible 
spectrophotometer. Cumulative percent of the drug 
released was determined at every point of time. The pure 
drug was used as a control. The T90 (time required for 90% 
dissolution of drug) of various solid dispersions were 
calculated.[17,18]
RESULTS AND DISCUSSION
Phase solubility analysis of silymarin
The phase solubility study was done to determine the 
stoichiometric proportion of silymarin with complexing 
agent b-cyclodextrin. The solubility analysis indicated 
the formation of a 1 : 1 molar inclusion complex of the 
drug with b-cyclodextrin. The apparent stability constant 
for silymarin (Kc) was 722 K−1 with the b-cyclodextrin 
complex.
Characterization of silymarin inclusion complexes
All the inclusion complexes prepared using different 
methods, such as, physical mixture, kneading method, co-
precipitation, and solvent evaporation method were found 
to be slightly brown, free-flowing powders.
Estimation of drug content
Inclusion complexes prepared by co-precipitation showed 
nearly 100% drug content. The drug content of the inclusion 
complex prepared by kneading, physical mixture, and solvent 
evaporation shows slightly less drug content as compared to 
that prepared by using co-precipitation [Table 1].
Scanning electron microscopy
Scanning electron microscopy (SEM) of the physical mixture 
method, inclusion complex by kneading method, and co-
precipitation method were studied. The representative 
photographs are shown in Figures 1–3. Pure drug particles 
in the physical mixture method were very small in size with 
reduced effective surface area, due to agglomeration. They 
remained dispersed and physically adsorbed on the surface 
of b-cyclodextrin. Figures 2 and 3, show drug particles 
distributed on the surface of b-cyclodextrin. Both kneaded 
and the co-precipitated systems show a homogeneity, 
signifying the inclusion complex formation. The kneaded 
system is of poor crystal structure, lacks distinct crystal 
faces, and has numerous cracks and fissures. This may 
also have contributed to faster dissolution compared to 
the co-precipitation system.
IR spectral analysis
Infra red spectra of the pure drug and inclusion of 
Table 1: Comparison of drug content and T90 value of 
silymarin inclusion complex with b-cyclodextrin
Systems % Drug content T90 (min)
Silymarin (alone) - <120
Silymarin : b cyclodextrin (PM) 97.140 62
Silymarin : b cyclodextrin (KN) 91.420 47
Silymarin : b cyclodextrin (CP) 99.995 94
Silymarin : b cyclodextrin (SE) 97.135 92
PM: Physical mixture, KN: Kneading, CP: Co-precipitation, SE: Solvent evaporation
Figure 1: Silymarin with b-cyclodextrin (Physical mixture)208   Journal of Young Pharmacists Vol 3 / No 3
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Figure 2: Silymarin with b-cyclodextrin (Kneading method)
Figure 3: Silymarin with b-cyclodextrin (Co-precipitation method)
Figure 4: IR spectra of inclusion complexes of silymarin with b-cyclodextrin (a) FT IR study of silymarin (b) Physical mixture method (c) Kneading 
method (d) Co-precipitation method (e) Solvent evaporation
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Table 2: Percentage cumulative release of inclusion 
complexes of silymarin and b-cyclodextrin prepared by 
different methods
Time %CR 
(Silymarin)
%CR 
(PM)
%CR 
(KN) 9
%CR 
(CP)
%CR 
(SE)
5 7.57 34.94 31.71 24.055 15.32
15 14.20 49.56 53.52 27.481 39.25
30 20.05 60.82 83.58 59.763 47.01
45 23.45 80.61 99.08 66.686 77.05
60 27.70 97.76 - 69.520 84.23
75 32.79 - - 87.200 86.41
90 43.67 - - 93.455 98.80
105 46.34 - - 95.320 -
120 49.13 - - - -
PM: Physical mixture, KN: Kneading, CP: Co-precipitation, SE: Solvent evaporation
silymarin with b-cyclodextrin, by different methods, are 
given in Figure 4 (a - e). The guest molecules within the 
cyclodextrin cavity show in their peaks or show peaks of 
less intensity. Basically peaks that lie in the fingerprint, and 
peaks due to C-O or O-H stretching are affected (shifted 
or intensity is changed).
Differential scanning calorimetric analysis
Silymarin, b-cyclodextrin, and the complex prepared by 
the co-precipitation method were subjected to Differential 
scanning calorimetric (DSC) analysis. The thermal curves 
are given in Figure 5. The DSC curve of silymarin shows 
one characteristic sharp endothermic peak at around 
150∞C, indicating the melting point of the drug. The DSC 
curve shows that the sharp endothermic peak at around 
150∞C, which is observed for silymarin, decreases in the 
inclusion complex (1:1). Furthermore, the wide peak at 
90∞C, which is observed for b-cyclodextrin, shifts to 60∞C 
in the inclusion complex, indicating that the inclusion 
complex does not contain much residue of silymarin 
or b-cyclodextrin, thus suggesting that the drug is well 
dispersed in the b-cyclodextrin cavity.
X-ray diffraction study
The inclusion complex of the drug prepared with 
b-cyclodextrin, using the co-precipitation method, which 
showed a good result overall, was characterized further 
by an XRD study The X-ray diffraction patterns of 
pure silymarin, as well as the silymarin–b-Cyclodextrin 
complex obtained by using the co-precipitation method 
are represented in Figure 6. The peak position (angle of 
diffraction) is an indication of the amorphous nature of the 
sample. The diffractogram of pure silymarin shows some 
intense peaks, which are indicative of crystallinity. However, 
in case of silymarin complexed with b-Cyclodextrin 
diffractogram, it attributes to a new solid phase with low 
crystallinity, indicating inclusion complex formation (more 
water soluble). A reduced number of signals, of markedly 
low intensity, are noticeable in the complex, indicating 
the greater amorphous nature of the inclusion complex 
compared to the free molecules.
Dissolution study of silymarin and its inclusion 
complexes
The inclusion complexes of silymarin with b-cyclodextrin 
produce pronounced enhancement in its dissolution as 
shown in Table 2 and Figure 7. From Table 1-T90 value 
for kneading shows the quickest rate of dissolution as 
compared to the other inclusion complexes, prepared by 
Figure 5: Differential scanning calorimetry study of silymarin, 
b-cyclodextrin and silymarin–b-cyclodextrin complex
Figure 6: X-ray diffraction study on silymarin and silymarin complexed 
with b-cyclodextrin
Figure 7: Dissolution profiles of inclusion complexes of silymarin and 
b-cyclodextrin prepared using different methods. PM = Physical mixture, 
KN = kneading, CP = co-precipitation, SE = solvent evaporation210   Journal of Young Pharmacists Vol 3 / No 3
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other inclusion methods. Inclusion complexes prepared 
by the co-precipitation methods show their T90 in about 
94 minutes.
CONCLUSION
The phase solubility data suggest a 1 : 1 complex formation 
with b-cyclodextrin. All inclusion complexes show increase 
in dissolution than in the drug alone. The inclusion complex 
of the drug prepared by the co-precipitation method 
shows the best results overall, in terms of drug content 
and dissolution profile, for preparation of sustained release 
formulations. However, it should be noted that this is a 
result of a preliminary study of b-cyclodextrin inclusion 
complexation with silymarin.
REFERENCES
1.  Luper SA. Review of plants used in the treatment of liver disease, Part 1. 
Altern Med Rev 1998;3:410-21.
2.  Pradhan SC, Girish C. Hepatoprotective herbal drug, Silymarin from 
experimental pharmacology to clinical medicine. Indian J Med Res 
2006;124:491-504.
3.  Reynolds JE. Martindale the Extra Pharmacopoeia. London: Pharmaceutical 
Press; 2002.
4.  Pepping J. Milk thistle: Silybum marianum. Am J Health Sys Pharma 
1999;56:1195-7.
5.  Saller R, Meier R, Brignoli R. The use of Silymarin in the treatment of liver 
diseases. Drugs 2001;61:2035-63.
6.  Pinnamaneni S, Das N, Das SK. Formulation approaches for orally 
administered poorly soluble drugs. Pharmazie 2002;57:291-300.
7.  Deshmukh SS, Potnis VV, Shelar DB, Mahaparale PR. Studies on 
inclusion complexes of ziprasone hydrochloride with b cyclodextrin and 
hydroxypropyl bcyclodextrin. Indian Drugs 2007;44:677-82.
8.  Patil JS, Pandya NR, Marapur SC, Shiralashetti SS. Influence of method of 
preparation on physiochemical properties and in vitro drug release profile 
of nimodipine–cyclodextrin inclusion complexes: A comparative study. Int 
J Pharmacy Pharmaceutical Sci 2010;2:71-81.
9.  Loftsson T, Brewster ME, Masson M. Role of cyclodextrins in improving 
oral drug delivery. Am J Drug Deliv 2004;2:1-15.
10.  Nagarsenkar MS, Meshram R, Ramprakash G. Solid dispersion of 
hydroxypropyl a cyclodextrin and Ketorolac: Enhancement of in vitro 
dissolution rates, improvement in anti-inflammatory activity and reduction 
in ulcerogenecity in rats. J Pharm Pharmacol 2000;52:949-56.
11.  Reddy MN, Chowdary KP, Diwan PV. b-Cyclodextrin complexes of 
celecoxib: Molecular modeling, characterization and dissolution studies. 
AAPS Pharm Sci 2004;6:E7.
12.  Loftsson T, Brewster ME. Pharmaceutical application of cyclodextrin in 
drug solubilisation and stabilization. J Pharm Sci 1996;85:1017-25.
13.  Kamal D, Ramana MD, Himaja M, Agarwal A, Garg V. Investigation of 
enhancement of solubility of norfloxacin beta cyclodextrin in presence of 
acidic solubilizing additives. Curr Drug Deliv 2007;4:21-5.
14.  Attma AA, Ndibe ON, Nnamani PO. Studies on diclofenac-b-Cyclodextrin 
inclusion complexes. J Pharm Res 2004;3:47-9.
15.  Soniwala MM, Patel PR, Ansuri MS, Parikh RK, Goel MC. Various 
approaches in dissolution enhancement of Rofecoxib. Indian J Pharm Sci 
2005;67:61-3.
16.  Aries MJ, Moyano JR, Munoz P, Justo A. Study of Omeprazole-g-
cyclodextrin complexation in the solid state. Drug Dev Ind Pharm 
2000;26:253-9.
17.  Becket G, Schep LJ, Tan MY. Improvement of the in vitro dissolution of 
praziquantel by complexation with α-, b-, and γ-cyclodextrin. Int J Pharm 
1999;179:65-71.
18.  Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJ. Cyclodextrins 
in the pharmaceutical field. Drug Dev Ind Pharm 1991;17:1503-49.
How to cite this article: Ghosh A, Biswas S, Ghosh T. Preparation and 
evaluation of silymarin β-cyclodextrin molecular inclusion complexes. J Young 
Pharmacists 2011;3:205-10.
Source of Support: Nil, Conflict of Interest: None declared.
Author Help: Online submission of the manuscripts
Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first 
page file and article file). Images should be submitted separately.
1)   First Page File: 
  Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should 
be included here. Use text/rtf/doc/pdf files. Do not zip the files.
2)  Article File: 
  The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any informa-
tion (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file 
size to 1024 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being 
incorporated in the article file. This will reduce the size of the file.
3)  Images: 
  Submit good quality color images. Each image should be less than 4096 kb (4 MB) in size. The size of the image can be reduced by decreas-
ing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable 
file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a 
good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.
4)  Legends: 
  Legends for the figures/images should be included at the end of the article file.